Ambit Biosciences Corporation

Citeline was delighted to be able to recognize and celebrate excellence across the Japanese pharma, biotech and clinical research industries at the 2nd Citeline Pharma Intelligence Awards Japan, held

Citeline was delighted to be able to recognize and celebrate excellence across the Japanese pharma, biotech and clinical research industries at the 2nd Citeline Pharma Intelligence Awards Japan, held

Daiichi Sankyo Co., Ltd. ’s quizartinib has received its first approval globally, in Japan, for the first-line treatment of FLT3 - internal tandem duplications (ITD) mutation-positive acute myeloid

Daiichi Sankyo Co., Ltd. looks set to press ahead with approval filings in major markets for its oral FLT3 inhibitor Vanflyta (quizartinib) in first-line FLT3-ITD-positive acute myeloid leukemia (AML